GlassScriptPhysician profile
Tetsuo Ishimori
NPI 1073716874
$757.94
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $128 · 2021: $45.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $359.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $129.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.65 | 2019-2021 | |
| Akcea Therapeutics, INC. | $54.82 | 2019-2020 | |
| Boston Scientific Corporation | $30.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.50 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.36 | 2019 | |
| Atricure, INC. | $16.24 | 2019 | |
| Amarin Pharma, INC. | $12.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tetsuo Ishimori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.